Evidence map›Paper›PMID 29045712›Full record

ArticleNeuro-oncology2018

Hospice utilization in patients with malignant gliomas.

Deborah Forst, Eric Adams, Ryan Nipp, Allison Martin, Areej El-Jawahri, Ayal Aizer, Justin T Jordan

Abstract read
In one paragraph

Article in Neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. End-of-Life Cancer Care Resource Utilisation in Rural Versus Urban Settings: A Systematic Review.International journal of environmental research and public health · 2020
    Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Nonprofit behavior altered by monetary donations: evidence from the U.S. hospice industry.The European journal of health economics : HEPAC : health economics in prevention and care · 2024
    Article
  14. Palliative Care in Neuro-oncology: an Update.Current neurology and neuroscience reports · 2023
    Review
  15. Article
  16. Article
  17. Disparities in place of death for patients with primary brain tumors and brain metastases in the USA.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  18. Review
  19. Neuro-oncology and supportive care: the role of the neurologist.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022
    Review
  20. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Deborah ForstDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
Eric AdamsDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.
Ryan NippDivision of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Allison MartinDepartment of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
Areej El-JawahriDivision of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Ayal AizerDepartment of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
Justin T JordanDepartment of Neurology, Massachusetts General Hospital, Boston, Massachusetts.

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Training Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3M
NCATS NIH HHS UL1 TR001102NCI NIH HHS K12 CA090354NIH HHS K12CA090354-13
6 · The paper itself

Abstract

Background: Despite recommendations from professional organizations supporting early hospice enrollment for patients with cancer, little research exists regarding end-of-life (EOL) practices for patients with malignant glioma (MG). We evaluated rates and correlates of hospice enrollment and hospice length of stay (LOS) among patients with MG. Methods: Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked database, we identified adult patients who were diagnosed with MG from January 1, 2002 to December 31, 2011 and who died before December 31, 2012. We extracted sociodemographic and clinical data and used univariate logistic regression analyses to compare characteristics of hospice recipients versus nonrecipients. We performed multivariable logistic regression analyses to examine predictors of hospice enrollment >3 or >7 days prior to death. Results: We identified 12437 eligible patients (46% female), of whom 7849 (63%) were enrolled in hospice before death. On multivariable regression analysis, older age, female sex, higher level of education, white race, and lower median household income predicted hospice enrollment. Of those enrolled in hospice, 6996 (89%) were enrolled for >3 days, and 6047 (77%) were enrolled for >7 days. Older age, female sex, and urban residence were predictors of longer LOS (3- or 7-day minimum) on multivariable analysis. Median LOS on hospice for all enrolled patients was 21 days (interquartile range, 8-45 days). Conclusions: We identified important disparities in hospice utilization among patients with MG, with differences by race, sex, age, level of education, and rural versus urban residence. Further investigation of these barriers to earlier and more widespread hospice utilization is needed.

Indexed as

AgedAge FactorsFemaleFollow-Up StudiesGliomaHospice CareHumansLength of StayMaleManaged Care ProgramsPrognosisRetrospective StudiesSEER ProgramSurvival Rate

Identifiers

PMID29045712
PMCPMC5909651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.